Paraneoplastic Syndrome Market Research Report Information By Type (Cutaneous Paraneoplastic Syndrome and Others), by Diagnosis (Blood Test, Spinal Tap, and Others), by Treatment (Medication and Others), by End User (Hospitals and Others)- Forecast till 2030

Paraneoplastic Syndrome Market Scenario

The paraneoplastic syndrome market is expected to grow USD 460 Million at a CAGR 5.80 % during the forecast period 2023 to 2030.
A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically seen in the middle-aged population to older population. This syndrome mostly occurs with patients suffering from lung, ovarian, or breast cancers.  
Numerous factors are anticipated to drive the growth of this market such as the increasing prevalence of cancer, consumption of tobacco, unhealthy lifestyle, increasing geriatric population, and increasing occurrence of breast cancer, among women. According to the American Autoimmune Association, 50 million people suffered from autoimmune disorders in the US in 2017.  
Increasing collaborations among various research institutes for the development of novel diagnostic techniques for the diagnosis of the paraneoplastic syndrome are expected to drive the growth of this market.
Despite the drivers, factors such as unfavorable reimbursement scenario and stringent regulatory policies may hamper the growth of the market during the assessment period.
Segmentation
The paraneoplastic syndrome market has been segmented into types, diagnosis, treatment, and end users. Based on types, the market is segmented into cutaneous paraneoplastic syndrome, gastro-intestinal paraneoplastic syndrome, endocrine paraneoplastic syndrome, hematologic paraneoplastic syndrome, renal paraneoplastic syndrome, rheumatologic paraneoplastic syndromes, and neurologic paraneoplastic syndrome.
The market on the basis of diagnosis has been segmented into blood test, spinal tap (lumbar puncture), and
imaging tests. Imaging tests are further sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and PET plus CT.
The market, by treatment, has been segmented into medication and therapies. Medication is further sub-segmented into corticosteroids, immunosuppressants, anti-seizure medications, plasmapheresis, and intravenous immunoglobulin (IVIg). On the basis of therapy, the market is further sub-segmented into physical therapy and speech therapy.
Based on end-user, the market is segmented into hospitals and clinics, diagnostic centers, and ambulatory care centers.
Key players
Some of the key players in the global paraneoplastic syndrome market are Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation,
York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.
Regional Market Summary

Global Paraneoplastic Syndromes Market Share (%), by Region, 2018

Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC)

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The paraneoplastic syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European paraneoplastic syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The paraneoplastic syndrome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The paraneoplastic syndrome market in the Middle East and Africa has been segmented into the Middle East and Africa.

Geographically, the Americas is anticipated to dominate the global paraneoplastic syndrome market. The market growth in this region is attributed to the increasing geriatric population with the paraneoplastic disorder, investment in research and development, and technological advancements. However, increasing approval of novel neurological diagnosis tools in this region is boosting the market in this region.

Europe is expected to be the second largest market in the globe owing to the increasing number of geriatric populations, increasing government expenditure for autoimmune disorders, the presence of disposable income, and increasing consumption of tobacco in this region.

Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of paraneoplastic disorder and cancer-related problems in developing countries, increasing disposable income, and growing healthcare expenditure.

The Middle East and Africa is expected to account for the lowest market share in the global paraneoplastic syndrome market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.

Global Paraneoplastic Syndrome Market, by Types

• Cutaneous Paraneoplastic Syndrome


• Gastro-Intestinal Paraneoplastic Syndrome


• Endocrine Paraneoplastic Syndrome


• Hematologic Paraneoplastic Syndromes


• Renal Paraneoplastic Syndrome


• Rheumatologic Paraneoplastic Syndromes


• Neurologic Paraneoplastic Syndrome

Global Paraneoplastic Syndrome Market, by Diagnosis

• Blood test


• Spinal tap (lumbar puncture)


• Imaging tests


• Computerized tomography (CT)


• Magnetic resonance imaging (MRI)


• Positron emission tomography (PET)


• PET plus CT

Global Paraneoplastic Syndrome Market, by Treatment

• Medication


• Corticosteroids


• Immunosuppressants


• Anti-seizure medications


• Medications to enhance nerve to muscle transmission


• Plasmapheresis


• Intravenous immunoglobulin (IVIg)


• Therapies


• Physical therapy


• Speech therapy

Global Paraneoplastic Syndrome Market, by End User

• Hospitals & Clinics


• Diagnostic Centers


• Ambulatory Care Centers

Global Paraneoplastic Syndrome Market, by Region

• Americas

• North America


• US


• Canada


• South America

• Europe

• Western Europe


• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe


• Eastern Europe

• Asia-Pacific

• Japan


• China


• India


• Australia


• Republic of Korea


• Rest of Asia Pacific

• Middle East & Africa

• Middle East


• Africa

Global Paraneoplastic Syndrome Market, by Key Players

• Healthineers


• Koninklijke Philips N.V.


• General Electric Company


• Esaote SpA


• NeuroLogica Corporation


• Masimo Corporation


• York Instruments Ltd


• Neusoft Medical Systems


• Canon Medical Systems Corporation

Intended Audience

• Hospitals and clinics


• Laboratories and associations


• Healthcare providers


• Research institutes and academic centers


• Government associations


• Market research and consulting

Report Attribute/Metric	Details
Market Size	460 Million
CAGR	5.80%
Base Year	2022
Forecast Period	2030
Historical Data	2021
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Types, Diagnosis, Treatment, and End users
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.
Key Market Opportunities	Increasing disposable income Growing healthcare expenditure
Key Market Drivers	Increasing collaborations among various research institutes for the development of novel diagnostic techniques for the diagnosis